Sign In
Buy RXRX
$3.52
+0.180 (+5.39%)
At Close: Jun 26, 2026
Recursion Pharmaceuticals (RXRX) Suffers a Larger Drop Than the General Market: Key Insights
06:50pm, Wednesday, 04'th Feb 2026
In the closing of the recent trading day, Recursion Pharmaceuticals (RXRX) stood at $3.9, denoting a -4.88% move from the preceding trading day.
Recursion Pharmaceuticals (RXRX) Declines More Than Market: Some Information for Investors
06:50pm, Thursday, 29'th Jan 2026
Recursion Pharmaceuticals (RXRX) reached $4.32 at the closing of the latest trading day, reflecting a -3.36% change compared to its last close.
Forget 2025: These 2 Growth Stocks Could Soar in 2026
05:55am, Thursday, 29'th Jan 2026
DraftKings' bulls were thrown an unexpected curveball, but this new competition doesn't carry the same brand-name cache. After years of development, Recursion Pharmaceuticals' AI-powered drug discover
Can This Beaten-Down AI Stock Bounce Back in 2026?
09:01pm, Wednesday, 28'th Jan 2026
Recursion Pharmaceuticals lagged the market last year. The stock doesn't have significant catalysts on the horizon.
The Genesis Mission Has a 270-Day Timeline – And You’re Already Late
12:00am, Tuesday, 27'th Jan 2026
The government is taking equity stakes in American companies. Here are the next Genesis Mission stocks to buy before the capital hits.
Baillie Gifford & Co. Sells 195,120 Shares of Recursion Pharmaceuticals, Inc. $RXRX
03:28am, Sunday, 25'th Jan 2026
Baillie Gifford and Co. lowered its stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) by 0.8% during the undefined quarter, according to its most recent disclosure with the Securities
Recursion Pharmaceuticals (RXRX) Stock Declines While Market Improves: Some Information for Investors
06:51pm, Friday, 23'rd Jan 2026
The latest trading day saw Recursion Pharmaceuticals (RXRX) settling at $4.73, representing a -4.64% change from its previous close.
Recursion Pharmaceuticals, Inc. (RXRX) Presents at 28th Annual Needham Growth Conference Transcript
02:54pm, Thursday, 22'nd Jan 2026
Recursion Pharmaceuticals, Inc. (RXRX) Presents at 28th Annual Needham Growth Conference Transcript
2 AI Stocks to Buy in 2026, and 1 to Avoid
04:45pm, Friday, 16'th Jan 2026
Tech giants Meta Platforms and Apple are capitalizing on their AI-related efforts. However, biotech upstart Recursion Pharmaceuticals' initiatives have yet to pay off.
Recursion Pharmaceuticals (RXRX) Stock Drops Despite Market Gains: Important Facts to Note
06:51pm, Thursday, 15'th Jan 2026
Recursion Pharmaceuticals (RXRX) closed at $4.65 in the latest trading session, marking a -4.12% move from the prior day.
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Receives $9.40 Consensus Price Target from Analysts
02:16am, Wednesday, 14'th Jan 2026
Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX - Get Free Report) have received a consensus rating of "Hold" from the six analysts that are covering the stock, MarketBeat.com reports. One res
Recursion Pharmaceuticals, Inc. (RXRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
05:46pm, Tuesday, 13'th Jan 2026
Recursion Pharmaceuticals, Inc. (RXRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Recursion to Present at 44th Annual J.P. Morgan Healthcare Conference
07:59am, Tuesday, 06'th Jan 2026
Salt Lake City, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its CEO & President, N
Recursion Pharmaceuticals (NASDAQ:RXRX) CFO Sells $89,380.94 in Stock
05:24am, Friday, 02'nd Jan 2026
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX - Get Free Report) CFO Ben Taylor sold 21,383 shares of the stock in a transaction on Monday, December 29th. The stock was sold at an average price of $4.
Bank Pictet & Cie Europe AG Acquires Shares of 1,630,000 Recursion Pharmaceuticals, Inc. $RXRX
03:34am, Friday, 02'nd Jan 2026
Bank Pictet and Cie Europe AG bought a new position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) in the third quarter, according to the company in its most recent 13F filing with the Se
